<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390971</url>
  </required_header>
  <id_info>
    <org_study_id>EDI-001</org_study_id>
    <nct_id>NCT04390971</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia</brief_title>
  <official_title>A Single Site, Open Label Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EdiGene Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single site study to evaluate the safety and Efficacy of ET-01
      Transplantation in subjects with Transfusion Dependent β-Thalassaemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After proper subject is recruited, subject will go through steps generally as stem cell
      mobilization, apheresis, conditioning and ET-01 infusion to complete therapy. 2 years' follow
      up visits will be carried out post-transplantation and related data will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of AEs &amp; SAEs identified according to NCI CTCAE 5.0.</measure>
    <time_frame>from ET-01 infusion to 104 weeks post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal laboratory test results after transplant</measure>
    <time_frame>from ET-01 infusion to 104 weeks post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal vital signs after transplant</measure>
    <time_frame>from ET-01 infusion to 104 weeks post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical significant abnormal vital signs.</measure>
    <time_frame>from ET-01 infusion to 60mins after ET-01 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with clinical significant abnormal vital signs.</measure>
    <time_frame>from ET-01 infusion to 60mins after ET-01 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality after ET-01 infusion.</measure>
    <time_frame>within 100 days post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment of ET-01 in subjects.</measure>
    <time_frame>within 42 days post-transplant</time_frame>
    <description>neutrophil count [ANC] &gt;500 /mm3 for 3 consecutive days or platelet count [PLT] &gt;20000/mm3 for 7 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total hemoglobin from baseline.</measure>
    <time_frame>within 104 weeks post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbF from baseline.</measure>
    <time_frame>within 104 weeks post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA from baseline.</measure>
    <time_frame>within 104 weeks post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of HbF/HbA.</measure>
    <time_frame>within 104 weeks post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of packed RBC transfusions.</measure>
    <time_frame>from 6 months before recruitment to 104 weeks post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in volume of packed RBC transfusions.</measure>
    <time_frame>from 6 months before recruitment to 104 weeks post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Transfusion Dependent Beta-Thalassaemia</condition>
  <arm_group>
    <arm_group_label>ET-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ET-01</intervention_name>
    <description>Recruited participants will receive ET-01 IV infusion after conditioning.</description>
    <arm_group_label>ET-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject and/or subject's legal personal representative fully understand and
             voluntarily sign informed consent forms;

          -  6~35 years old, all gender, weight ≥ 30kg;

          -  Genetically diagnosed β-Thalassaemia;

          -  Diagnosed as transfusion-dependent;

          -  Eligible for autologous stem cell transplant;

          -  Organs in good function;

          -  Other protocol defined Inclusion criteria may apply.

        Exclusion Criteria:

          -  Thalassemia gene type is β0/β0;

          -  Active bacterial, virus, fungal or parasitic infection, including HIV infection, HbsAg
             and HBV DNA positive, HCV DNA positive, or Treponema Pallidum infection;

          -  HLA identical sibling or unrelated donors are available;

          -  Prior allo-HSCT or gene therapy;

          -  Other protocol defined Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Shi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Shi, PhD</last_name>
    <phone>(86)2223900913</phone>
    <email>shijun@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingyu Zhao, MPH</last_name>
    <phone>(86)13752253515</phone>
    <email>zhaojingyu@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Shi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Jun Shi</investigator_full_name>
    <investigator_title>Director of Regenerative Medicine Clinic Center</investigator_title>
  </responsible_party>
  <keyword>Beta-Thalassaemia</keyword>
  <keyword>Hematopoietic Stem-Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

